Who we are ?

PlexBio Co., Ltd. (6572), established in December 2009, is a leading Taiwanese in vitro diagnostic reagent developer and manufacturer with its self-developed Precision Image Code MicroDisc (πCode™), advanced patented technology, and IntelliPlex™ testing system.

We provide accurate medical solutions for quality health care

PlexBio Co., Ltd. (6572), established in December 2009, is a leading Taiwanese in vitro diagnostic reagent developer and manufacturer with its self-developed Precision Image Code MicroDisc (πCode™), advanced patented technology, and IntelliPlex™ testing system.

With its cross-era core detection technology, Precision Image Code MicroDisc can detect dozens to hundreds of biomarkers with just one single specimen, facilitating the practice and application of clinical diagnosis and precision medicine.

In particular, the company has focused on cancer diagnosis and monitoring, developing a reagent platform covering hundreds of mutations and using non-invasive liquid biopsy for simultaneous analysis of a large number of patient specimens.

Carrying the determination to do scientific research we pursue the ultimate quality

With πCode MicroDisc's innovative technology, we expect to further revolutionize and enhance the development of the diagnostic industry.

Plexbio Focused On Providing More Accurate, Convenient And Cost-competitive Products

PlexBio is dedicated to the development of innovative, high-performance, and diversified in vitro diagnostic reagents for molecular biology and immunology projects. For the past three consecutive years, we have been honored as one of the top 500 tech companies in the Asia-Pacific region, making us a leading brand and significant player in the global in vitro assay market..
  • Precise

    Leveraging our core competencies to acquire the ability to accurately determine mutations, we meet customer needs precisely
  • Speedy

    The capability to expand instantly responds quickly to market needs
  • Simple and Convenient

    Ease-of-use platform has been developed to streamline the process of experimental operation and improve the performance of experimental operations.
  • Economic

    The affordable cost raises our competitiveness in the market.

New Strategies for Cancer Treatment Future Trends in Liquid Biopsy

With the rise in demand for precision medicine and companion diagnostics, the development of liquid biopsy assays has consequently taken place.
Since liquid bioassays are performed using only body liquids (e.g. blood, urine, fluids in lungs, etc.), they are less invasive and the specimens are relatively easy to collect. PlexBio understands the suffering of patients who cannot undergo tissue biopsy and has invested heavily in the development of various cancer genomic profiling reagents and platforms.
Liquid biological specimens can be applied to monitor the effectiveness of treatment for patients and to evaluate drug and surgical efficacy. They also create novel opportunities for early detection and diagnosis of cancer and other major diseases.

您目前為透過後台登入模式

Please Enable cookies to improve your user experience

Continue